Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)

@inproceedings{Wiggermann2011TransarterialCO,
  title={Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)},
  author={Philipp Wiggermann and Dominik Sieroń and Christiane Brosche and Thomas Brauer and Fabian Scheer and Ivan Platzek and Wojciech Wawrzynek and Christian Stroszczynski},
  booktitle={Medical science monitor : international medical journal of experimental and clinical research},
  year={2011}
}
BACKGROUND This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis. MATERIAL/METHODS A comparison of interventional therapy with either cTACE or DEB-TACE of 22 patients each with unresectable HCC and Child-Pugh A Cirrhosis was carried out. A comparison of therapy-associated complications, tumour response rates and mean… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis.

  • International journal of clinical and experimental medicine
  • 2014
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations.

  • HPB : the official journal of the International Hepato Pancreato Biliary Association
  • 2015
VIEW 12 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

MRI-Compatible Injection System for Magnetic Microparticle Embolization

  • IEEE Transactions on Biomedical Engineering
  • 2018
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 1 EXCERPT

Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis.

  • Medical science monitor : international medical journal of experimental and clinical research
  • 2009
VIEW 1 EXCERPT

A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.

  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2007
VIEW 2 EXCERPTS

Similar Papers